Evidence map›Paper›PMID 40379771›Full record

ArticleScientific reports2025

Synthesis and evaluation of quinolinvinyl-phenoxy-1,2,3-triazole-acetamide hybrids against breast cancer.

Maliheh Safavi, Aida Iraji, Sara Moghadam Farid, Mohammad Mahdavi, Samaneh Fattaheian-Dehkordi, Tahmineh Akbarzadeh, Mina Saeedi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maliheh SafaviIranian Research Organization for Science and Technology (IROST), Tehran, Iran.
Aida IrajiTraditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara Moghadam FaridEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Samaneh Fattaheian-DehkordiMedicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Tahmineh AkbarzadehDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mina SaeediPersian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran. m-saeedi@tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work synthesized and evaluated a new series of quinolinvinyl-phenoxy-1,2,3-triazole-acetamide hybrids 9a-p against breast cancer cell lines, including MCF-7 and MDA-MB-231. Among 16 synthesized compounds, (E)-N-(4-chlorophenyl)-2-(4-((4-(2-(quinolin-2-yl)vinyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)acetamide (9f) was the most active compound on both cell lines, with IC

Indexed as

AcetamidesAntineoplastic AgentsBreast NeoplasmsTriazolesApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsStructure-Activity RelationshipacetamideAcetamidesAntineoplastic AgentsTriazoles1,2,3-triazoleAnti-cancerApoptosisQuinolinvinyl

Identifiers

PMID40379771
PMCPMC12084587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.